MARKET

MBIO

MBIO

Mustang Bio
NASDAQ
0.6762
+0.0171
+2.59%
Closed 19:29 02/02 EST
OPEN
0.6600
PREV CLOSE
0.6591
HIGH
0.7001
LOW
0.6600
VOLUME
363.73K
TURNOVER
--
52 WEEK HIGH
1.200
52 WEEK LOW
0.3150
MARKET CAP
71.15M
P/E (TTM)
-0.8616
1D
5D
1M
3M
1Y
5Y
Mustang Bio (MBIO) Investor Presentation - Slideshow
Seeking Alpha · 01/27 23:52
BRIEF-Mustang Bio Provides Car T Cell Therapy Portfolio Updates
Reuters · 12/19/2022 13:37
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates And 2023 Anticipated Milestones
Benzinga · 12/19/2022 13:36
BRIEF-Mustang Bio Says On Nov 22, Notified By Nasdaq That Nasdaq Had Granted Co's Request To Transfer Listing Of Co's Common Stock To Nasdaq Capital Market Tier
Reuters · 11/25/2022 22:09
BTIG Maintains Buy on Mustang Bio, Lowers Price Target to $4
Benzinga · 11/16/2022 12:48
--BTIG Adjusts Mustang Bio's Price Target to $4 From $8, Keeps Buy Rating
--BTIG Adjusts Mustang Bio's Price Target to $4 From $8, Keeps Buy Rating
MT Newswires · 11/16/2022 09:31
--Oppenheimer Adjusts Mustang Bio Price Target to $4 From $8, Maintains Outperform Rating
--Oppenheimer Adjusts Mustang Bio Price Target to $4 From $8, Maintains Outperform Rating
MT Newswires · 11/16/2022 09:23
Mustang Bio GAAP EPS of -$0.18 beats by $0.02
Seekingalpha · 11/14/2022 23:45
More
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that is focused on translating medical breakthroughs in cell and gene therapies into cures for hematologic cancers, solid tumors and rare genetic diseases. The Company's pipeline is focused on three core areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. Its products include MB-107 and MB-207 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency (XSCID). XSCID is a rare genetic immune system condition also known as bubble boy disease. It is developing CAR T therapies for hematologic malignancies in partnership with COH targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). The Company is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105).

Webull offers kinds of Mustang Bio Inc stock information, including NASDAQ:MBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBIO stock methods without spending real money on the virtual paper trading platform.